Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need spun out of research institute MRC Laboratory of Molecular Biology, floated on the Nasdaq Global Market yesterday following a $60.7m initial public offering. The company issued approximately 4.3 million American Depositary Shares, equivalent to the same number of ordinary shares, priced…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.